- Home
- TOP vs EPIX Comparison
TOP vs EPIX Comparison
Compare TOP & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOP
- EPIX
- Stock Information
- Founded
- TOP 2015
- EPIX 2009
- Country
- TOP Hong Kong
- EPIX Canada
- Employees
- TOP N/A
- EPIX N/A
- Industry
- TOP Investment Bankers/Brokers/Service
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- TOP Finance
- EPIX Health Care
- Exchange
- TOP Nasdaq
- EPIX Nasdaq
- Market Cap
- TOP 61.5M
- EPIX 73.5M
- IPO Year
- TOP 2022
- EPIX N/A
- Fundamental
- Price
- TOP $1.35
- EPIX $1.61
- Analyst Decision
- TOP
- EPIX Hold
- Analyst Count
- TOP 0
- EPIX 3
- Target Price
- TOP N/A
- EPIX $2.00
- AVG Volume (30 Days)
- TOP 105.3K
- EPIX 302.9K
- Earning Date
- TOP 01-29-2025
- EPIX 12-17-2024
- Dividend Yield
- TOP N/A
- EPIX N/A
- EPS Growth
- TOP N/A
- EPIX N/A
- EPS
- TOP 0.03
- EPIX N/A
- Revenue
- TOP $8,037,105.00
- EPIX N/A
- Revenue This Year
- TOP N/A
- EPIX N/A
- Revenue Next Year
- TOP N/A
- EPIX N/A
- P/E Ratio
- TOP $44.20
- EPIX N/A
- Revenue Growth
- TOP N/A
- EPIX N/A
- 52 Week Low
- TOP $1.35
- EPIX $1.40
- 52 Week High
- TOP $7.77
- EPIX $11.67
- Technical
- Relative Strength Index (RSI)
- TOP 30.69
- EPIX 24.10
- Support Level
- TOP $1.52
- EPIX $1.63
- Resistance Level
- TOP $1.79
- EPIX $1.74
- Average True Range (ATR)
- TOP 0.09
- EPIX 0.06
- MACD
- TOP -0.02
- EPIX 0.10
- Stochastic Oscillator
- TOP 2.22
- EPIX 5.41
About TOP TOP Financial Group Limited
TOP Financial Group Ltd is an online brokerage firm in Hong Kong specializing in trading local and overseas equities, futures, and options products. The Company generates brokerage commission income by enabling its customers to trade on multiple exchanges present globally. The company operates in only one segment which is the futures brokerage service.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.